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Abstract
Background: Expression of the retinoic acid receptor β2 (RAR-β2), a putative tumor suppressor
gene, is reduced in various human cancers, including squamous cell carcinomas (SCC) of the uterine
cervix. The mechanism of the inhibition of RAR-β2 expression remains obscure. We examined
whether methylation of RAR-β2 gene could be responsible for this silencing in cervical SCC.
Methods: Expression of RAR-β2 mRNA and methylation status of the 5' region of RAR-β2 gene
were examined in 20 matched specimens from patients with cervical SCC and in three cervical
cancer cell lines by Northern blot analysis and methylation-specific PCR (MSP) assay or Southern
blot analysis respectively.
Results: In 8 out 20 cervical SCC (40%) the levels of RAR-β2 mRNA were decreased or
undetectable in comparison with non-neoplastic cervix tissues. All 8 tumors with reduced levels of
RAR-β2 mRNA expression showed methylation of the promoter and the first exon expressed in
the RAR-β2 transcript. The RAR-β2 gene from non-neoplastic cervical tissues was mostly
unmethylated and expressed, but methylated alleles of the gene were found in three samples of the
morphologically normal tissues adjacent to the tumors. Three cervical cancer cell lines with
extremely low level of RAR-β2 mRNA expression, SiHA, HeLA and CaSki, also showed
methylation of this region of the RAR-β2 gene.
Conclusions: These findings suggest that methylation of the 5' region of RAR-β2 gene may
contribute to gene silencing and that methylation of this region may be an important and early event
in cervical carcinogenesis. These findings may be useful to make retinoids more effective as
preventive and therapeutic agents in combination with inhibitors of DNA methylation.
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Vitamin A and its biologically active metabolites, the
retinoids, are essential for the maintenance of normal ep-
ithelial differentiation [1]. Retinoid-deficient epithelial
tissues acquire a premalignant phenotype, which is char-
acterized by enhanced mitotic activity and loss of differen-
tiation [2]. Retinoids have been used as chemopreventive
and chemotherapeutic agents for various human cancers
[3].
The antiproliferative and differentiative effects of retin-
oids are mediated through two classes of nuclear recep-
tors, the RARs and RXRs. Both classes consist of three
members, α, β and γ [4]. All these receptors are ligand-ac-
tivated transcription factors. They activate transcription by
binding to retinoic acid response elements (RAREs) locat-
ed in the promoter regions of the target genes. One of the
targets of retinoid receptors is the RAR-β gene itself. The
RAR-β gene encodes for four transcripts and is expressed
in normal epithelial tissue, where its expression is up-reg-
ulated by treatment with retinoic acid (RA) [5,6]. Recent
studies have demonstrated that in many malignant cell
lines derived from various carcinomas the level of RAR-β2
mRNA (one of four transcripts of this gene) is decreased
or undetectable [7–9]. A decrease of RAR-β2 mRNA level
(compared to normal tissues) was also observed in carci-
nomas of cervix [10], and in carcinomas of head and neck
[11]. These findings indicate that the specific loss of RAR-
β2 mRNA expression may be an important event in tu-
morogenesis. This hypothesis has been supported by an
observation that RAR-β2 can function as a tumor suppres-
sor gene in two different carcinoma cell lines [12,13].
Thus, a defect in RAR-β2 expression may be one of the
events that lead the tumor cells to the escape from growth
regulation.
The etiology of cancer of the uterine cervix has been asso-
ciated with several types of human papillomaviruses
("high-risk" HPVs) [14]. In addition to growth regulation,
the product of RAR-β gene can inhibit transcription of the
viral oncogenes (E6 and E7 genes) in high-risk HPV-im-
mortalized cells [15]. The decrease of the expression of
negative regulator of viral oncogene may be an additional
important step on the way towards malignant progression
of HPV-positive cells in this case.
It has been shown that the retinoic acid can induce an in-
crease of RAR-β2 expression in carcinoma cells [16] and in
lesions of the oropharynx [17]. RA treatment has inhibit-
ed transformation of human keratinocytes by HPV-16
[18] and has enhanced regression of cervical moderate
dysplasia [19]. Beneficial effects of RA treatment of ad-
vanced cervical squamous cell carcinomas (in combina-
tion with interferon α) have been demonstrated in clinical
trials [20]. On the other hand, the existence of retinoic
acid-insensitive cancer cell lines, including cervical carci-
noma cell lines, and the lack of clinical effects of retinoids
treatments in some cases are well established [21,22].
The mechanism of the down-regulation and the loss of
RA-inducible expression of RAR-β2 in cervical carcinomas
and cell lines derived from them is not well understood
yet. Recent findings have shown that hypermethylation of
the promoter region is implicated in the transcriptional si-
lencing of many tumor suppressor genes and several other
genes functionally important in neoplastic process [23].
The promoter regions of many genes, including RAR-β2,
contain CpG islands, that are protected from methylation
in normal cells [24]. Aberrant methylation of CpG islands
in tumors serves as an alternative pathway (in addition to
intragenic mutations and loss of chromosomal loci) for
complete inactivation of tumor suppressor genes. Hyper-
methylation of normally unmethylated CpG islands in
the 5' region of the RAR-β2 gene has been observed in
breast and colon cancer cell lines, that do not express RAR-
β2 mRNA [25–29].
In this study we examined whether the methylation could
be responsible for the deficit of RAR-β2 gene expression in
cervical squamous cell carcinomas.
Materials and Methods
Tissue specimens
Specimens of cervical tumor were collected in the Depart-
ment of Radiosurgery of Russian Cancer Research Center:
20 specimens of invasive squamous cell carcinoma with
low and moderate levels of differentiation and I, II and III
FIGO stages and 20 specimens of morphologically nor-
mal tissues of cervix from the same patients. All tumors
were HPV16- or HPV18-positive by PCR analysis.
Cell lines
The human cervical carcinoma cell HeLa, SiHa and CaSki
(American Type Culture Collection, Rockville, MD) were
maintained in DMEM, supplemented with 10% FCS and
2 mM glutamine.
DNA and RNA preparations
DNA and RNA were isolated from frozen tissues homoge-
nized in the 4.5 M solution of guanidine thiocyanate by
centrifugation through cesium chloride cushion, as de-
scribed previously [30].
Northern blot analysis
10 µg of total RNA was fractionated in 0.8% formalde-
hyde agarose gel and transferred to "Hybond C extra" ni-
trocellulose membrane (Amersham, UK) according to
Sambrook et al. [31]. The membranes were hybridized
with 32P-labelled 650 bp and 610 bp EcoRI fragments of
RAR-β2-specific DNA. In order to control the relativePage 2 of 7
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eraldehyde-3-phosphate dehydrogenase (GAPDH) DNA
probe. Hybridization was performed in 5 × SSC at 42°C in
the presence of 50% formamide. The membranes were
washed in 2 × SSC, 1% SDS at 65°C and were exposed to
X-ray film at -70°C.
Southern blot analysis
10 µg of DNA was digested overnight with MspI or HpaII
restriction enzymes (10 units/µg of DNA, SibEnzyme,
Novosibirsk, Russia). The restriction fragments were sepa-
rated in 1% agarose gel, transferred to nylon membrane
(Zeta-Probe, Bio-Rad, USA) and hybridized with 32P-la-
belled PCR DNA probe. PCR DNA probe was prepared by
PCR amplification of a 680 bp fragment of RAR-β2 pro-
moter and exon_3 with primers: forward, 5'-ATT TGA
AGG TTA GCA GCC CG and reverse 5'-CAT TCG GTT TGG
GTC AAT CC, in the following conditions: 94°C for 3 min,
30 amplification cycles (94°C, 30 sec; 56°C, 30 sec; 72°C,
1 min) and 72°C, 5 min . Hybridization and washing con-
ditions were as described for RNA.
Methylation-specific PCR (MSP) assay [32]
Bisulfite conversion reaction was carried out according to
S.J. clark et al. [33] with minor modifications. DNA (2 µg)
was digested with RsaI restriction enzyme (SibEnzyme,
Novosibirsk, Russia), denaturated by addition of NaOH
to a final concentration 0.3 M, incubated for 15 minutes
at 37°C and 3 minutes at 95°C, followed by cooling on
ice. Sodium bisulfite and hydroquinone were added to
the denatured DNA to final concentration 3.6 M and 0.5
mM, respectively. The sample was overlaid with mineral
oil and incubated at 65°C for 16 hours. The DNA was pu-
rified using QIAEX II kit (Qiagen), desulfonated by addi-
tion of NaOH to a final concentration 0.3 M and
incubation at 37° for 15 min, neutralized with 3 M am-
monium acetate (pH 7.0), precipitated with 3 volumes of
ethanol, resuspended in H2O and stored at -20°C.
Primers that were specific for the upper strand of bisulfite-
modified DNA and did not contain CpG dinucleotides in
the original sequences were used in the first round of PCR:
forward 5'-AAG TGA GTT GTT TAG AGG TAG GAG GG
and reverse 5'-CCT ATA ATT AAT CCA AAT AAT CAT TTA
CC [28]. 5-20 ng of DNA was amplified with these prim-
ers in the following conditions: 94°C, 5 min; 35 amplifi-
cation cycles (94°C, 15 sec; 53°C, 15 sec and 72°C, 30 sec)
and 72°C, 5 min. The obtained DNA fragments were am-
plified in the second round of PCR with two set of primers
specific for the upper strand of bisulfite-modified DNA,
which contains CpG dinucleotides: 1) forward 5'-TTG
AGA ATG TGA GTG ATT TGA and reverse 5'-AAC CAA
TCC AAC CAA AAC AA for the unmethylated sequence
(U), 2) forward 5'-TCG AGA ACG CGA GCG ATT CG and
reverse 5'-GAC CAA TCC AAC CGA AAC GA for the meth-
ylated sequence (M). The PCR was performed under the
following conditions: 94°C, 2 min; 40 cycles (94°C, 30 s;
50°C, 30 s and 72 °C, 30 s for U-primers) and 35 cycles
(94°C, 30 s; 58°C, 30 s and 72°C, 30 s for M-primers) and
72°C, 5 min. The PCR products were fractionated in the
3% agarose gel and photographed.
Results
RAR-β2 mRNA expression
The level of the expression of RAR-β2 mRNA was evaluat-
ed in 20 samples of invasive squamous cell carcinomas of
uterine cervix at low and moderate levels of differentia-
tion and in the morphologically normal tumor-adjacent
tissues of cervix in order to select a group of tumors with
deficient expression of RAR-β2 (Figure 1B, Table 1). The
level of RAR-β2 mRNA expression was significantly de-
creased in 8 out of 20 tumors constituting 5 – 48% of the
expression level of the corresponding morphologically
normal tissue. An extremely low (undetectable) level of
mRNA expression was observed in one tumor, as well as
in the adjacent morphologically normal tissue (Fig. 1B,
lanes 5,6; Table 1, case 7). Thus, in 40% of cervical SCC
the expression of the RAR-β2 mRNA was significantly de-
creased. An extremely low level of mRNA expression, wich
was observed earlier in three cell lines HeLA, SiHa and
CaSki [22], was confirmed in our experiment (data are not
presented).
Methylation status of the RAR-β2 5' region
The methylation status of the 5' region of the gene was
studied in order to determine if this DNA modification,
which inhibits transcription, contributes to the inhibition
of the expression of the RAR-β2 mRNA. The study was car-
ried out by two independent methods: by Southern blot
analysis and by methylation-specific PCR assay. The local-
ization of the recognition sites for the methylation-sensi-
tive restriction enzyme Hpa II within the promoter region
and the first transcribed exon of the RAR-β2 transcript (ex-
on 3) is presented on the fig. 1A. The sizes of the frag-
ments, which are produced when the restriction sites are
methylated and can not be digested by Hpa II, are indicat-
ed in the lower part of the fig. 1A. The control digestion of
DNA by Msp I (cuts at the identical to Hpa II site even if
the cytosine residue is methylated) produced only one
major band 1.1 kbp (Fig. 1C, lanes 1, 3, 5, 7, 9, 11, 13,
15). The absence of the 1.1 kbp band, as well as that of
1.15 – 1.6 kbp, after the digestion of the DNA by Hpa II
indicates that the H1-H5 sites are methylated (Fig. 1C,
lanes 8, 10, 12, 14, 16). The presence of 1.1 kbp band and
the absence of any additional bands indicates that these
sites are unmethylated (Fig 1C, lanes 2, 4, 6). As demon-
strated by Southern blot analysis, all analyzed sites were
methylated in 6 out of 8 carcinomas with the deficit of the
RAR-β2 mRNA (Table 1). It was impossible to perform
this analysis in two carcinomas due to lack of adequatePage 3 of 7
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A. Restriction map of promoter-exon region of RARβ2 gene for methylation-sensitive Hpa II enzyme. The bolt
line shows the 680 bp DNA probe generated by PCR of the promoter and exon 3. The expected fragment sizes which are rec-
ognized by this probe are shown in the bottom part of the map. The transcription start site is indcated by broken arrow. The
positions of the primers for MSP assay are indicated by arrows. The 146 bp fragment is the region analyzed for CpG methyla-
tion by MSP assay. The triangles show the positions of two RAREs within the promoter region. H – HpaII sites, the positions of
the Hpa II sites in relation to the trascription start site are indicated by fugures in bp. B. Northern blot analysis of total
RNA isolated from cervical carcinomas (T) and adjacent cervical normal tissues (N). The blots were hybridized
with 32P labeled DNA probes for RARβ2 and GAPDH. Lanes1, 2 – 4N, 4T, lanes 3, 4 – 5N, 5T, lanes 5,6 – 7N, 7T respectively.
Case numbers correspond to that indicated in table 1. The arrows show the positions of 28S and 18S RNA. C. Southern blot
analysis of DNA isolated from cervical carcinomas (T) and adjacent cervical normal tissues (N). The blots were
hybridized with 680 bp 32P labeled DNA probe for RARβ2. The bold arrow shows the positions of a minimal 1.1 kbp fragment,
recognized by this probe. Lanes 1, 3, 5, 7, 9, 11, 13, 15 – DNA digested by MspI; lanes 2, 4, 6, 8, 10, 12, 14, 16 – DNA digested
by HpaII; lanes 1, 2 – 9N; lanes 3, 4 – 9T; lanes 5,6 – 4N; lanes 7, 8 – 4T; lanes 9, 10 – 7N; lanes 11,12 – 7T; lanes 13,14 – SiHa;
lanes 15, 16 – HeLa. Case numbers correspond to that indicated in table 1. D. MSP assay of DNA isolated from cervical
carcinomas (T), adjacent cervical normal tissues (N) and leucocytes (L). All DNA samples were treated with sodium
bisulfite before amplification of a 146 bp fragment with methylation-specific primers (M) and unmethylation-specific primers
(U). Sample numbers on the top of the gel correspond to that indicated in table 1; mr – molecular weight marker.
A Exon 3                                          
(-264) (-191) (-61)TATA (+161) (+237) ATG
  H1 H2 H3  H4 H5                                   H6
500                      700                       900                        1100                      1300              
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                                                               1.1 kb
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                     1.4 kb
   1.5 kb
1.6 kb
                                 F-bis    F-M,U  R-M,U R-bis
146 bp
B          1      2     3      4    5     6     
RARbeta2                                                                                                             
GAPDH                                                          
C                                                                            
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D
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the morphologically normal tissue in the case 7 (Fig. 1C,
lane 10). This result correlated with the absence the
mRNA expression in this samples (Fig. 1B, lane 5). Two
cervical cancer cell lines, showed methylation of this re-
gion also (Fig 1C, lanes 14, 16).
The same samples were subjected to the MSP assay. The
MSP assay allows detection of methylated, as well as of
unmethylated alleles after the modification of DNA by so-
dium bisulfite. The presence of nonmalignant cells (fi-
broblasts, blood cells and some normal epithelial cells) in
tumor specimens does not interfere with the ability to de-
tect methylation. The sensitivity of this assay to detect
methylated alleles in the background of unmethylated al-
leles is > 10-4[32]. The result of a typical experiment with
a set of primers, that amplify a 146 bp product in the re-
gion of H4 and H5 sites of Hpa II (5' untranslated region,
5' UTR), is presented on the fig. 1D. The presence of an
amplification product obtained in the reaction with me-
thyl-specific primers (M) indicates for the methylation
(Fig. 1D, samples IT, 3T, 7T). The absence of this product
indicates for the absence of the methylated alleles (Fig.
1D, samples 13T, 9T, 13L and all N samples). Amplifica-
tion with primers, which are specific for the unmethylated
sequence (U), demonstrated that this region is mostly
demethylated. It should be noted, that in all tumor sam-
ples, that bear the methylated alleles, we detected at least
traces of the products of amplification with U primers. Ap-
parently, the nonmalignant cells, that are present in tu-
mor specimens serve as a source of this product. Both
primer pairs (M and U) do not react with DNA, which was
not treated with bisulfite (data not shown). Thus, the
presence of an amplification product in the reaction with
the U primers serves as a control of a correct DNA modifi-
cation by bisulfite in the case of a negative reaction with
the M primers. The results of the MSP assay confirmed the
methylated status of DNA in the 5' UTR region of RAR-β2
gene in tumors with decreased level of mRNA expression
and in all cervical cancer cell lines examined. (Table 1). In
addition to one case, which was detected by Southern blot
analysis, two patients were found to produce a poor am-
plification with the M primers in morphologically normal
tissues (data not shown).
Thus, methylation of CpG site in the promoter and the 5'
UTR region of RAR-β2 gene was detected in all 8 tumor
samples with deficient expression of the RAR-β2 mRNA
and all cervical cancer cell lines. Methylation of this region
was not found in the tumors with normal expression lev-
els of the RAR-β2 mRNA.
Discussion
RAR-β2 is a putative tumor suppressor. Complete or par-
tial inhibition of the expression of the gene was observed
in many tumor cell lines and in primary human tumors
[7–11,22]. It was demonstrated in this study, that in 8 out
of 20 SCC of cervix a deficient expression of the RAR-β2
mRNA was observed in comparison to the matched mor-
phologically normal tissue of cervix.
The mechanism of the inhibition of RAR-β2 expression re-
mains obscure. It was demonstrated in the tumor cells
lines derived from breast and colon carcinomas, that the
expression of RAR-β2 mRNA is silenced by methylation of
the promoter and the first exon, that is expressed in the
RAR-β2 transcript. Treatment of DNA by demethylating
agent 5-aza-2'-deoxycytidine restored the inducibility of
the gene by all-trans-retinoic acid (ATRA) in many, but not
all tumor cell lines. For breast carcinomas a relationship
between methylation status and decreased RAR-β2 expres-
sion was found only in invasive grade II tumors. In grade
III tumors the RAR-β2 expression was never observed, re-
gardless the methylation status [28]. In all 8 invasive SCC
of cervix and in three cell lines, analyzed in our study, the
deficit of the expression of the RAR-β2 mRNA was associ-
ated with methylation of the promoter and the region of
the first exon, including the H3 site close to the RARE (Fig-
ure 1A). The methylation of this site plays an important
role in the repression of the gene transcription in the
breast cancer cells [29]. However, recently 5 cervical can-
cer cell lines were revealed in that the inhibition of the
RAR-β2 mRNA expression was not associated with the
methylation of the same region of the gene [34]. Appar-
ently, some other events together with methylation of the
promoter region are involved in gene inactivation in cer-
Table 1: Methylation Status of RAR β2 5' region in cervical SCC 
and cervical cancer cell lines







1 5 nd M
2 19 M Nd
3 48 M M
4 22 M M
5 26,5 M M
6 18 M M
7 ** M M
8 19 nd M
9-20 95-103 U U
HeLa ** M M
SiHa ** M M
CaSki ** nd M
* The expression levels of RAR β2 mRNA in carcinomas relative to 
morphologically normal tissues (%), determinations by Northern blot 
analysis; the RAR β2 mRNA levels have been normalized to GAPDH. 
** Expression of RAR β2 mRNA was extremely low in tumor and 
morphologically normal tissue or cell lines. nd – not donePage 5 of 7
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lar, overexpression of Nur 77 gene has been found to be
associated with a loss of RAR-β2 inducibility and RA re-
sistance in lung cancer cells [35].
In our study the methylated alleles of RAR-β2 were absent
in the majority of morphologically normal tissues of cer-
vix. However, methylated alleles of the gene were found in
three samples of the normal tissue, which were adjacent to
the tumors with methylated status of RAR-β2. It can be
suggested, that methylation of the normal tissues of cervix
is an early preneoplastic event, that favours the develop-
ment of malignancy. Our data provide only indirect evi-
dence that methylation and the loss of RAR-β2 expression
are early steps of cervical carcinogenesis. Recently this sug-
gestion was supported by the study, where the methylated
alleles of the gene were found in 11% and 29% of low
grade and of high grade cervical intraepithelial neoplasias
respectively [34]. This authors found the methylation of
RAR-β2 gene in 5 out of 17 invasive carcinomas also. Tak-
en together these data indicate that methylation of RAR-
β2 gene is frequent and early event during cervical can-
cerogenesis.
Conclusions
These findings suggest that methylation of the 5' region of
RAR-β2 gene may contribute to gene silencing and that
methylation of this region may be an important and early
event in cervical carcinogenesis. Cervical carcinomas may
serve as a potential target for the DNA methylation inhib-
itors due to a close correlation between the deficit of RAR-
β2 mRNA expression and methylation of this gene. These
inhibitors in combination with retinoids might be clini-
cally useful in future as chemopreventive and chemother-
apeutic agents for patients with cervical dysplasias and
carcinomas.
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